Beatriz Pinho

Beatriz Pinho

Auto-generated profile, based on publicly available information

Beatriz Pinho

Neurosciences and Signalling Group, Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, Aveiro Portugal

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Tânia Cristina Soares MartinsTânia Cristina Soares Martins
Tânia Cristina Soares Martins
SPSteven Pelech
Steven Pelech
MFMaria José Ferreira
Maria José Ferreira
BPBeatriz Pinho
Beatriz Pinho
KLKevin Costa Leandro
Kevin Costa Leandro
AHAna Gabriela Henriques
Ana Gabriela Henriques
Phosphorylation plays a key role in Alzheimer’s disease (AD) pathogenesis, impacting distinct processes such as amyloid-beta (Aβ) peptide production and tau phosphorylation. Impaired phosphorylation events contribute to senile plaques and neurofibrillary tangles’ formation, two major histopathological hallmarks of AD. Blood-derived extracellular particles (bdEP) can represent a disease-related source of phosphobiomarker candidates, and hence, in this pilot study, bdEP of Control and AD cases were analyzed by a targeted phosphoproteomics approach using a high-density microarray that featured at least 1145 pan-specific and 913 phosphosite-specific antibodies. This approach, innovatively applied to bdEP, allowed the identification of 150 proteins whose expression levels and/or phosphorylation patterns were significantly altered across AD cases. Gene Ontology enrichment and Reactome pathway analysis unraveled potentially relevant molecular targets and disease-associated pathways, and protein-protein interaction networks were constructed to highlight key targets. The discriminatory value of both the total proteome and the phosphoproteome was evaluated by univariate and multivariate approaches. This pilot experiment supports that bdEP are enriched in phosphotargets relevant in an AD context, holding value as peripheral biomarker candidates for disease diagnosis.

1 December 2024 in Alzheimer's & Dementia
Verified
Journal Article
Open access
BPBeatriz Pinho
Beatriz Pinho
MVMargarida Vaz
Margarida Vaz
TMTânia Soares Martins
Tânia Soares Martins
OSOdete da Cruz e Silva
Odete da Cruz e Silva
AHAna Gabriela Henriques
Ana Gabriela Henriques
Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder marked by the development of amyloid plaques and neurofibrillary tangles in the brain, which contribute to synaptic dysfunction and extensive neuronal loss. Protein phosphorylation is a key event in AD pathogenesis. Glycogen synthase kinase 3 (GSK3) is a serine/threonine kinase with two isoforms, GSK3α and GSK3β. While GSK3β link with AD is well stablished, the role of GSK3α in AD is not fully understood. Few studies suggest that GSK3α can be involved in tau phosphorylation, amyloid‐beta (Aβ) production, and neuronal cell death. Hence, the objective of this study was to test GSK3α levels and its potential contribution to AD.Method: Two AD‐mimicking models were employed, SH‐SY5Y treated with the Aβ peptide and SH‐SY5Y carrying the Swedish mutation of APP695. Cell lysates were subjected to Western Blot analysis to monitor total protein levels and phosphorylation of both GSK3 and its isoforms α and β.Result: Significant differences in the GSK3 total levels and in specific phosphorylation sites associated with protein activation were obtained for both isoforms in AD mimicking conditions.Conclusion: This research supports that GSK3α is altered in disease conditions and offers new insights of GSK3 involvement in AD pathology. This research was supported by iBiMED UIDB/04501/2020 and UIDP/04501/2020, FCT, the COMPETE program, QREN, and the European Union. M.V. is supported by the FCT through the individual PhD grant UI/BD/151354/2021.